Health Care

Medtronic plc (NYSE:MDT) Q3 2023 revenue of $7.727 billion

/ / Health Care /

Feb. 21, 2023 – Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Q3 revenue of $7.7 billion was essentially flat year-over-year and exceeded market expectations of $7.53 billion. Non-GAAP earnings per share were $1.3, beating market expectations of $1.27. Medtronic reported third quarter worldwide revenue of $7.727 billion, a flat result as reported and an increase of 4.1% on an organic basis. GAAP diluted EPS of $0.92 decreased 16%; non-GAAP diluted EPS of $1.30 decreased 4%, ahead of expectations. Third quarter U.S. revenue of $4.062 billion represented approximately 52% of company revenue and increased 3% as reported and 2% organic. Non-U.S. developed market revenue of $2.294 billion represented 30% of company revenue and decreased 6% as reported and increased 6% organic. Emerging Markets revenue of $1.371 billion represented 18% of company revenue and decreased 1% as reported and increased

Medtronic plc (NYSE:MDT) Q3 2023 revenue of $7.727 billion Read Post »

Raymond James: Lowered CVS Health (NYSE:CVS) price target to $110 from $115 Outperform

/ / Health Care / ,

Raymond James analyst John Ransom lowered its price target on CVS Health (NYSE:CVS) to $110 from $115 and maintained the stock’s “outperform” rating. The analyst told investors in a research note that CVS Health’s fourth-quarter results were in line with their pre-announcement, that guidance for 2023 remained unchanged, and that the company announced the acquisition of Oak Street Health, a health firm on Oak Street.

Raymond James: Lowered CVS Health (NYSE:CVS) price target to $110 from $115 Outperform Read Post »

CVS Health (NYSE:CVS) Total revenues increased to $83.8 billion, up 9.5% YoY in Q4 2022

/ / Health Care /

February 8, 2023 – CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2022. Q4 adjusted earnings Wednesday of $1.99 per diluted share,Analysts polled by Capital IQ expected $1.93. Revenue for the quarter ended Dec. 31 was $83.8 billion, Analysts surveyed by Capital IQ expected $76.4 billion. The company said it expects full-year 2023 adjusted earnings of $8.70 to $8.90 per diluted share. Analysts polled by Capital IQ expect $8.86. FOURTH QUARTER HIGHLIGHTS： Total revenues increased to $83.8 billion, up 9.5% compared to prior year. GAAP diluted EPS of $1.75 and Adjusted EPS of $1.99. Announced a 10% increase to the quarterly shareholder dividend, which became effective with the February 1, 2023 dividend distribution. Returned $2.9 billion to shareholders through dividends, while repurchasing 34.1 million shares of common stock and authorizing a new $10.0 billion share repurchase program. Increased unique digital customers by seven million

CVS Health (NYSE:CVS) Total revenues increased to $83.8 billion, up 9.5% YoY in Q4 2022 Read Post »

Abbvie Inc. (NYSE:ABBV) Q4 2023 Adjusted Profit, Revenue Rises; Sets Outlook for 2023

/ / Health Care /

Abbvie Inc. (NYSE:ABBV) reported Q4 adjusted earnings Thursday of $3.60 per diluted share,Analysts polled by Capital IQ expected $3.58. Revenue for the quarter ended Dec. 31 was $15.12 billion, Analysts surveyed by Capital IQ expected $15.30 billion. For the full year of 2023, the company is expecting adjusted earnings of $10.70 to $11.10 per diluted share. Analysts polled by Capital IQ are expecting $11.68.

Abbvie Inc. (NYSE:ABBV) Q4 2023 Adjusted Profit, Revenue Rises; Sets Outlook for 2023 Read Post »

Scroll to Top